Therapy News and Research

RSS

Side effects may limit use of Prometheus's Lotronex for IBS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.

5 Apr 2010

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.

5 Apr 2010

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

Individualized therapies for treating type 2 diabetes recommended

Chevy Chase, MD-Patients with type 2 diabetes are generally treated similarly despite the fact that they may have underlying differences that could affect their therapeutic response. Seeking to address this critical health issue, an international multidisciplinary group of experts just issued recommendations for individualized treatment in a consensus statement to be published in the April 2010 issue of the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

5 Apr 2010

Request for lift of full clinical hold on Proellex program

Repros Therapeutics Inc. today announced that the Company has requested a lift of the full clinical hold on its oral drug Proellex® being developed for the treatment of uterine fibroids and endometriosis. On August 4, 2009, the FDA noted that further testing of Proellex® was placed on full clinical hold due to findings of serious adverse events associated with liver toxicity.

5 Apr 2010

SIGVARIS introduces Athletic Recovery Sock Line for athletes

Medically endorsed SIGVARIS created the Athletic Recovery Sock Line for competitive athletes and weekend warriors as compression garments have become highly visible in all major sports. Whether it's during the actual event, after the event, or even while traveling, athletes are making graduated compression socks part of their everyday attire.

5 Apr 2010

A1C test for diagnosing diabetes must be reevaluated: Journal of Diabetes

As a benchmark for diagnosing diabetes, the importance of the A1C test must be reevaluated to improve glycemic numeracy of policy makers, patients and providers - who must make real-world decisions. This is based on a commentary published by Wiley-Blackwell in the Journal of Diabetes.

5 Apr 2010

Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the company will participate in a panel discussion on Personalized Medicine for the Treatment of Multiple Sclerosis on April 7, 2010.

5 Apr 2010

Is relief round the corner for multiple sclerosis patients in the form of bee stings?

A recent development can raise the hopes of many sufferers of Multiple Sclerosis (MS) – a dreaded, debilitating, fatal nerve disorder. Charity worker Sami Chugg, 45, claims to have overcome her condition after being stung by bees.

5 Apr 2010

Diabetic tests must be regulated

As a benchmark for diagnosing diabetes, the importance of the A1C test must be reevaluated to improve glycemic numeracy of policy makers, patients and providers – who must make real-world decisions. This is based on a commentary published by Wiley-Blackwell in the Journal of Diabetes.

5 Apr 2010

KMI receives 2-year Phase II SBIR grant to study new treatment for TBI

Kinetic Muscles Inc., a leading innovator of neurorehabilitation technology, announced it has received a 2-year Phase II SBIR grant to study a new treatment for veterans returning from active duty with traumatic brain injury.

5 Apr 2010

WCU: Dental Hygiene Clinic to offer free dental hygiene services at Anaheim campus

West Coast University has announced that the Dental Hygiene Clinic at its Anaheim campus will offer the public free dental hygiene services ranging from oral inspection and risk assessment, to digital and traditional imaging (X-rays), to preventative therapies and non-surgical periodontal therapy (cleanings).

5 Apr 2010

Clinical utility and pharmacological action of MN-166 in treatment of MS

MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).

3 Apr 2010

Physiotherapist-led exercise helps postnatal women reduce risk of PND

In a world first study of its kind, 161 postnatal women with no previous depressive symptoms were divided in two separate groups to test the effect of a physiotherapist-led exercise and education program on wellbeing.

3 Apr 2010

Identification and elimination of cancer stem cells

A new field of cancer research could explain why some cancers that appear to have been cured can rear their ugly head or spread to other organs.

3 Apr 2010

Cancer research at Georgia Tech: Report

Cancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient's age and general health, and other factors.

3 Apr 2010

Study: Trial vaccine eliminates residual cancer cells in CML patients

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

3 Apr 2010

Notch pathway may be a good target for drug development, study says

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells -- a small population of cells within tumors that perpetuate cancer growth -- conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.

3 Apr 2010

Ultrasound and light for determining tumor's response to therapy in early stages

A biomedical scientist at Ryerson University in Toronto, Canada is exploring how ultrasound and light can be used to measure the effectiveness of cancer treatment in the early stages of therapy. By comparing high-frequency ultrasound patterns before and after treatment, doctors can potentially know within days if a tumor is responding to a prescribed therapy.

3 Apr 2010

Harnessing body's own natural killer cells to battle cancer in children

Work underway at St. Jude Children's Research Hospital seeks to harnesses the body's own immune cells known as natural killer, or NK, cells to help children battle cancer. NK cells are the immune system's warriors. The cells circulate widely in the body, armed with proteins, called enzymes, capable of delivering a deadly one-two punch to viruses and cancer cells.

3 Apr 2010